Boston Scientific Corporation expanded its Board of Directors from ten to twelve members with the appointments of Catherine R. Smith and Christophe P. Weber. Additionally, the Board approved a $4.0 billion increase to its existing share repurchase authorization, bringing the total amount available for common stock repurchases to $5.0 billion.
